NKTR Stock Forecast: Nektar Therapeutics Price Predictions for 2026-2027
The median 12-month analyst price target for Nektar Therapeutics is $150. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Nektar Therapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (74): The business earns solid, repeatable profits on what it owns.
Accruals (7): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NKTR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NKTR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Canaccord Genuity | Maintains | Buy | $153 → $149 |
| 12 Oct 2026 | Leerink Partners | Initiates | Outperform | $130 |
| 12 Oct 2026 | UBS | Initiates | Neutral | $53 |
| 9 Oct 2026 | BTIG | Reiterates | Buy | $178 |
| 9 Oct 2026 | Raymond James | Initiates | Market Perform | — |
| 2 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $185 |
| 28 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 25 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 23 Sept 2026 | Wedbush | Maintains | Neutral | $80 → $50 |
| 16 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 9 Sept 2026 | BTIG | Reiterates | Buy | $178 |
| 21 Aug 2026 | JP Morgan | Reinstates | Neutral | $65 |
| 22 July 2026 | Canaccord Genuity | Initiates | Buy | $153 |
| 11 May 2026 | Wedbush | Maintains | Neutral | $95 → $80 |
| 8 May 2026 | Piper Sandler | Maintains | Overweight | $105 → $192 |
| 21 Apr 2026 | Citigroup | Maintains | Buy | — |
| 21 Apr 2026 | Wedbush | Maintains | Neutral | — |
| 20 Apr 2026 | BTIG | Maintains | Buy | — |
| 20 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2026 | Wedbush | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NKTR.
This page is one stock. Monday covers all of them.
NKTR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NKTR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Nektar Therapeutics returned −45.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NKTR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 20.9×
- Price / book
- 1.3×
- EV / EBITDA
- —
Cheaper than 7% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −37.9%
- Return on assets
- −14.8%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nektar Therapeutics has a market value of $1.1B and an enterprise value of $627.7M.
Revenue in the twelve months to 30 June 2026: $54.6M. The latest quarter shrank 9.3% year on year.
Net income over the same four quarters: −$157.1M, a −287.8% net margin.
Diluted earnings per share, trailing twelve months: −$6.70.
Free cash flow in the twelve months to 30 June 2026: −$234.0M.
Nektar Therapeutics employs 63 people — $866K of revenue per employee.
Data provided by Twelve Data
NKTR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NKTR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Nektar Therapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NKTR
What is the NKTR stock price forecast for 2026-2027?
The median 12-month analyst price target for Nektar Therapeutics is $150, with estimates ranging from $40 to $192. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NKTR stock a buy right now?
Of the 15 analysts covering Nektar Therapeutics, 11 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nektar Therapeutics 40 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NKTR?
As at 21 Nov 2026, Nektar Therapeutics ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (74 of 100).
Will NKTR stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts is $150, and Ticker Nerd's factor model ranks Nektar Therapeutics 40 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NKTR stock forecast for 2030?
No analyst covering Nektar Therapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NKTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $192 over the next 12 months.
How has NKTR stock performed over the past year?
Nektar Therapeutics returned -45.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nektar Therapeutics do?
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes.
About Nektar Therapeutics.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, being evaluated in clinical programs for conditions such as atopic dermatitis, alopecia areata, and type 1 diabetes. The company also advances additional candidates across autoimmune, fibrotic, and cancer-related areas, including programs targeting ulcerative colitis, vitiligo, multiple sclerosis, and solid tumors. Through its proprietary chemistry and immunology expertise, Nektar Therapeutics develops highly selective therapeutic candidates intended to modulate key biological pathways and support precision treatment approaches across specialty disease areas.
CEO Mr. Howard W. Robin · 63 employees · United States · https://www.nektar.com